Comparative analysis identifies SOX as the most cost-effective treatment for advanced gastric cancer, suggesting its preference in Japan.
At a willingness-to-pay threshold of USD 100,000/QALY (Japan's HTA upper reference), SOX was identified as the most cost-effective first-line treatment for HER2-negative unresectable advanced or recurrent GC in Japan.
No takes yet. Share an insight, caveat, or question.
Morimoto et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: